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Abstract 
Background: Female sexual dysfunction (FSD) is a vast problem in the medical community and in the 
world. It affects more than just sexual experiences of women and their partners, but also vitality and 
many other aspects of health. Female Sexual Arousal Disorder (FSAD) is one subcategory of FSD 
disorders. Since arousal has been found to be a key component in the female sexual response cycle, 
possible treatments would ideally target local arousal. Topical alprostadil has been proposed to be a 
vasodilator and could possibly affect chemoreceptors locally in the genitalia. Thus, it is a probable 
treatment for the many women who live with FSAD. 
Methods: An exhaustive search of available medical literature was conducted utilizing MEDLINE-Ovid, 
CINAHL, and Web of Science. Keywords used to search were alprostadil, sexual dysfunction and female. 
GRADE was utilized to evaluate the evidence 
Results: Two journal articles were found that met all the inclusion and exclusion criteria. A dose related 
response was found for improvement of FSFI scores, sexual arousal rates, and sexual satisfaction vs. 
placebo in both studies. The rates of sexual arousal and sexual satisfaction were significantly higher in 
the 400 mcg group in the Heiman et al, 2006 study and the 900 mcg group of the Liao et al, 2008 study. 
Adverse events were low in all treatment groups, and lowest in the placebo, 100 mcg, 500 mcg and 700 
mcg groups respectively. 
Conclusion: Topical alprostadil is an effective and safe treatment option for patients with FSAD. This 
treatment significantly improved sexual arousal rates and sexual satisfaction for most all treatment 
groups. 
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Abstract 
Background: Female sexual dysfunction (FSD) is a vast problem in 
the medical community and in the world. It affects more than just 
sexual experiences of women and their partners, but also vitality and 
many other aspects of health. Female Sexual Arousal Disorder (FSAD) 
is one subcategory of FSD disorders. Since arousal has been found to 
be a key component in the female sexual response cycle, possible 
treatments would ideally target local arousal. Topical alprostadil has 
been proposed to be a vasodilator and could possibly affect 
chemoreceptors locally in the genitalia. Thus, it is a probable 
treatment for the many women who live with FSAD.  
Methods:  An exhaustive search of available medical literature was 
conducted utilizing MEDLINE-Ovid, CINAHL, and Web of Science. 
Keywords used to search were alprostadil, sexual dysfunction and 
female. GRADE was utilized to evaluate the evidence 
Results:  Two journal articles were found that met all the inclusion 
and exclusion criteria. A dose related response was found for 
improvement of FSFI scores, sexual arousal rates, and sexual 
satisfaction vs. placebo in both studies. The rates of sexual arousal 
and sexual satisfaction were significantly higher in the 400 mcg group 
in the Heiman et al, 2006 study and the 900 mcg group of the Liao et 
al, 2008 study. Adverse events were low in all treatment groups, and 
lowest in the placebo, 100 mcg, 500 mcg and 700 mcg groups 
respectively.  
Conclusion:  Topical alprostadil is an effective and safe treatment 
option for patients with FSAD. This treatment significantly improved 
sexual arousal rates and sexual satisfaction for most all treatment 
groups.  
Keywords:  Alprostadil, female sexual dysfunction, female sexual 
arousal disorder 
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Effectiveness of Topical Alprostadil in the 
Treatment of Female Sexual Arousal Disorder 
BACKGROUND 
Female sexual dysfunction (FSD) which is a multidisciplinary, 
distressing group of disorders which encompasses many symptoms 
such as low sexual desire, decreased sexual arousal, and discomfort 
during sexual activity1 plagues many women. For example, in 1999 
Laumann et al2 polled almost 3000 men and women, which was the 
first survey to be conducted like this since the Kinsey era, to 
determine rates of sexual dysfunction in the United States. Their 
research found 43% of the women who were surveyed had been 
experiencing some kind of sexual dysfunction, as compared to 31% of 
the male subjects.2 More recent reports3 have yielded similar results, 
showing women with sexual concerns at 40%. 
Sexual dysfunction is not only an issue with satisfaction and 
arousal rates, but also with the overall health of the human being. 
There have been statistically significant correlations between sexual 
dysfunction and decreases in mental health, social function, 
relationship problems, undiagnosed medical conditions and overall 
vitality.1 Cardiovascular risk factors have also been correlated in 
several studies4 with women who have clitoral and vaginal dysfunction 
as well. Therefore there is a large need for treatments to be 
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researched and studied for efficacy and safety, not only for sexual 
function but for overall health. A number of treatments are on the 
market for male patients with sexual dysfunction, but very few are 
available for women. Frankly, this is unacceptable due to these serious 
risks and ramifications that dysfunction of sexual health can affect 
both men and women. 
Female sexual arousal disorder (FSAD) is one of the many 
subtypes of FSD that involves “…the persistent or recurrent inability to 
attain, or to maintain sufficient sexual excitement and satisfaction, 
causing personal distress.”5 Since FSAD typically involves the 
excitement phase of the sexual experience, topical alprostadil has 
been suggested as a potential treatment for this disorder due to its 
proposed mechanism of action and its safety.  
Topical alprostadil is a prostaglandin E1 (PGE1) which is naturally 
occurring in humans and is a vasodilator.1 Clinicians have tried other 
vasodilators for the treatment of sexual dysfunction in women, such as 
sildenafil--a PDE5 inhibitor, but these studies6 have resulted in no 
decisive conclusions due to varying populations and measurements as 
well as genital engorgement without any subjective arousal. Thus, the 
mechanism of alprostadil, as of yet is not fully understood. Sun et al7 
studied the mechanism by applying alprostadil to female rats, 
concluding that there must be some other chemoreceptor mechanism 
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and/or hormone response in the brain that is different from other 
vasodilator treatments. Another potential benefit of topical alprostadil 
may be its potential to decrease systemic side effects, unlike other 
current treatment suggestions for FSAD.  
Alprostadil as a treatment also conceptually makes sense when 
looking at female sexual response in general. Levine et al8 theorizes 
that desire is a complex part of the sexual experience that 
encompasses both sexual drive and sexual motivation. This builds on 
the idea that was proposed by Basson9 in the late 1990’s, that the 
precursor to desire for females is often sexual arousal, since most 
females tend to start a sexual encounter from a position of sexual 
neutrality. Thus treating sexual arousal may be the key to helping 
many sexual function disorders and an integral piece to the FSD 
puzzle.   
METHODS 
An exhaustive literature search was performed using the follow 
search engines: MEDLINE-Ovid, CINAHL, and Web of Science. The key 
terms which were searched included alprostadil, sexual dysfunction 
and female. The following eligibility criteria was applied to each of 
these studies: studies published in the English language, studies which 
were conducted on human women 22-70 years of age who were all 
diagnosed with female sexual dysfunction, and studies that were 
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published after May 2006 or were not included in Kielbasa, L et al 
literature review titled Topical Alprostadil Treatment of Female Sexual 
Arousal Disorder10 and studies which compared topical Alprostadil with 
placebo treatments. Articles were assessed for quality using the Grade 
of Recommendations, Assessment, Development and Evalution.11 
RESULTS 
The search of the 3 databases yielded a total of 55 articles. 
These studies and articles were run through the inclusion criteria and 2 
studies resulted.5,12 See Table 1. 
Heiman et al, 2006 
 The Heiman et al12 study measured outcomes in 79 
postmenopausal or hysterectomized women ages 40-70 and their 
response to either 100 mcg of topical alprostadil or 400 mcg of topical 
alprostadil in a prospective, randomized, multicenter, double-blind, 
crossover design study. Each subject was also given a placebo dose 
which was compared to their response to the allotted alprostadil dose. 
These doses were administered in the clinic and were immediately 
followed by 60 minutes of video stimulation which was selected 
according to sexual orientation and from most commonly requested 
videos from a female audience.12 
Subjects were periodically asked to rate their overall genital 
wetness, pelvic fullness, warmth/tingling, any pain, sexual arousal, 
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satisfaction with the level of arousal and sexual satisfaction itself, as 
well as overall physical comfort. Vital signs were also assessed on each 
subject and investigators assessed the erythema and edema of the 
genitalia immediately before dosing, and at 60 minutes and 120 
minutes afterwards.12  
This Heiman et al12 study included subjects who were mostly 
white EuroAmericans, married, satisfied with their current relationship 
and all of who were diagnosed with FSAD. Baseline scores of the 
Female Sexual Function Index (FSFI; this index measures different 
aspects of sexual function on a scale of 0 to 6 for at total of 19 
questions) and the Female Sexual Distress Scale (FSDS) were 
conducted prior to the study in all the participating women. There was 
no significant difference between the dosage groups for these 
demographic parameters.12 
When the observers rated genital vasocongestion at 60 minutes 
and 120 minutes for each of the doses of alprostadil, 100 mcg and 400 
mcg, there was a significant local vasodilatory response for both 
groups at each time increment. In terms of pelvic fullness, the 100mcg 
dose did not show significant difference between placebo scores, 
however, the 400 mcg dose group showed a significant change, 
peaking at 30 minutes, when compared the placebo.12 
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Genital warmth and tingling were both significantly greater in the 
100 mcg and the 400 mcg doses compared to placebo, with the 400 
mcg group showing a greater significant difference over the entire 120 
minutes (6.95 vs. 2.74; p=0.002).12 Genital wetness and lubrication 
did not significantly change between 100 mcg, 400 mcg and placebo, 
but the changes from baseline over a 2 hour observational period 
significantly increased for all study groups, including placebo.12 
Sexual arousal levels were significantly different from baseline in 
both the 100 mcg and the placebo groups. However, there was no 
significant difference between these 2 groups. On the other hand, the 
400 mcg dose group vs. placebo did show a significant difference, and 
especially when summed up as a change over baseline over the entire 
120 minutes (5.42 vs. 2.61; p=0.017).12 
Satisfaction with the level of sexual arousal was significant for 
both alprostadil and the placebo, but this was not the case between 
each treatment group. Sexual satisfaction was very similar to the 
results of sexual arousal levels. Both the 100 mcg and placebo 
resulted in significantly different results than baseline, but not when 
compared to each other. On the contrary, the 400 mcg group showed 
a significantly greater sexual satisfaction rate than the placebo group 
over the entire 120 minutes of observation (4.74 vs. 2.42; p=0.015).12 
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Pain ratings and physical discomfort showed no significant 
difference between baseline or one another. In terms of adverse 
events for the 100 mcg group, 28% of subjects treated with 100 mcg 
dose of alprostadil and 18% of subjects treated with the placebo 
reported adverse events. These included genital erythema, which was 
the most common reported event, genital edema, and genital burning. 
All of these cases were considered mild to moderate in severity. Within 
the 400 mcg group, 50% of subjects reported adverse events and 
32% of the placebo reported adverse events as well. These events 
were the same for the 100 mcg group above in terms of events and 
the severity.12 
Liao et al, 2008 
This study5 took the Heiman et al, 2006 study to another level 
with the number of participants and a slightly different study design. 
Liao et al was a multicenter, randomized, double-blind parallel and 
placebo-controlled study that took 374 female participants of which 
were non-menopausal (268 participants) and post-menopausal (106). 
Their mean age was 45 years, ranging from 22-62. All of the female 
participants showed no significant differences when it came to medical 
history or FSDS and FSFI scores, and all were screened via strict 
eligibility criteria including having a diagnosis of FSAD and currently 
being in a stable monogamous relationship.5 
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Participants in the Liao et al study were randomly assigned to 1 
of 4 groups, 1 group was placebo and the others were differing levels 
of topical alprostadil 500 mcg, 700 mcg, and 900 mcg. All of the 
patients received 10 identical, placebo matched, individually packaged 
plastic dispensers with white cream. These were applied by the patient 
to the clitoris and anterior vaginal G-spot 5-30 minutes prior to 
anticipated sexual intercourse. Patients were required to attempt 
sexual intercourse 5 times during three 4-week windows and record 
their responses in a patient diary which included the Female Sexual 
Encounter Profile (FSEP), the FSFI, the Female Sexual Distress Scale 
(FSDS), and the global assessment questionnaires (GAQ).5 
The outcomes for sexual arousal rates showed a significantly 
higher rate as compared to baseline across all placebo and treatment 
groups. Also, when comparing all the treatment groups to placebo, 
these scores for sexual arousal were all significantly higher in the 
treatment groups than the placebo (Table 2). When looking specifically 
at change between each of the individual treatment group and 
placebo, the 500mcg treatment group and placebo was not significant, 
but the differences between the 700 mcg, the 900 mcg vs. placebo did 
show significant differences (Table 2) in terms of sexual arousal rate. 
These two groups also showed significantly higher scores in the areas 
of sexual satisfaction with overall sex life as well.5 
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There were significant differences in all measured areas of the 
FSFI when comparing the 900 mcg group to placebo. These included 
desire, arousal, lubrication, orgasm, satisfaction, and pain. This trend 
also held true for the FDSD score as well. Sexual satisfaction was 
measured with the GAQ which resulted in a significant increase in all 3 
dose groups when compared to placebo.5 
Adverse events were reported as well throughout the study 
groups. The most frequent adverse events included genital burning, 
itching, swelling, irritation, or soreness which were mostly all rated 
mild or moderate in intensity. These adverse events were highest in 
the 900 mcg group, similar in the 500mcg and 700 mcg group and 
lowest in the placebo group. Five of the patients withdrew due to 
adverse events.5 
DISCUSSION 
The data and results of both studies5,12 analyzed showed that 
topical alprostadil is indeed a possible treatment in treating women 
with FSAD. Both of the studies demonstrated a positive response in 
the measured outcomes of sexual arousal rates and sexual satisfaction 
by the participants. This was confirmed by the use of FSDS and FSFI 
which are both reliable and valid measures of female sexual 
dysfunction, which demonstrated increased rates of sexual satisfaction 
and arousal, rated by participants. Both of these rates were linked 
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most significantly to the administration of the higher dose of 
alprostadil, 400 mcg in the Heiman et al12 and 900 mcg in the Liao et 
al.5 Thus, indicating a dose related response gradient.  
Both studies5,12 alluded to the physiological response of the 
female body to alprostadil, but in different ways. It has been 
postulated that alprostadil increases intracellular cyclic adenosine 
monophosphate (cAMP) and activation of protein kinase A resulting in 
vasodilation. 1 Heiman et al12 found this to be indeed true as observed 
by the raters of increased erythema and edema with the use of the 
alprostadil vs. placebo and in subject reports of sexual arousal and 
satisfaction. Liao et al5 echoed this information; however, he 
postulated that due to an increase in subjective reports of sexual 
satisfaction, which differed from reports of women who have tried to 
use sildenafil, which has been physiologically proven to be a 
vasodilator in men, then there must be another action of alprostadil 
that needs further study. They reported that other studies have 
suggested the influence on neurotransmitters or reflexes via 
chemoreceptors. Sun et al7 took this theory to the next level when 
they applied alprostadil to the vagina of rats. Their study showed 
significantly increased expression of oxcytocin-immunoreactive (OT-
IR) cells and c-fos-immunoreactive (c-fos-IR) cells in the 
paraventricular nucleus of the hypothalamus (PVN) which supports the 
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theory discussed in the Liao et al study,5 suggesting alprostadil’s 
potential action on the genital nerve terminals signaling the brain.7 
Whenever a new medication such as alprostadil is proposed, 
benefit vs. harm is always an important decision in its practical use. 
First of all, topical alprostadil is a local application, and thus, will most 
likely avoid many side effects which are associated with a systemic 
delivery method for the medication. 1 Both studies5,12 looked at adverse 
events and the safety of topical alprostadil and both found it to have 
minimal adverse side effects. Most frequently reported adverse event 
in the Liao et al5 was irritation and signs and symptoms at the 
application site such as burning, itching, swelling, irritation and 
soreness. These reported signs and symptoms were very similar to the 
most commonly reported by the Heiman et al study12 participants as 
well which included genital erythema (18% of subjects), genital edema 
and genital burning. Additionally, there seems to be a dose related 
response in terms of adverse events, which was seen in both 
studies5,12 with the larger amounts of alprostadil (400 mcg and 900 
mcg) reporting the highest number of adverse events. However, as 
stated in the results, no patients in the Heiman et al12 stopped due to 
adverse events, but 5 patients withdrew from the Liao et al study5 due 
to adverse events and those patients were either in the 700 mcg or 
900 mcg group. However, 5 patients dropping out in a large study is 
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not significant if the benefits are indeed present for most people. Also, 
interestingly in the Heiman et al study, 12 overall ratings of comfort of 
the application did not differ significantly between the treatment and 
placebo groups; thus it was tolerated well by both groups. 
When analyzing the subject demographics in both studies, 5,12 
there are a lot of similarities between the subject groups in terms of 
FSFI scores and mean ages, especially for the Heiman et al study12 
who only looked at postmenopausal or hysterectomized women. Also, 
Liao et al5 and Heiman et al12 both included patients whom had FSAD. 
Neither study distinguished between patients who may be diagnosed 
with a subcategory of FSAD. Thus, one must take into consideration 
the similarity of each of the groups who were studied. Also, in the 
Heiman et al study, 12 most of the women were white (79%) and in the 
Liao et al study,5 most women were Han (up to 89% of the group). 
This makes sense due to the location in which both the studies were 
conducted and their mean ethnic population. However, it must be 
considered that some cultures have differing views on sex, and 
especially when it comes to satisfaction and arousal that women 
experience during sex. Sexual expectations and norms also differ 
across cultures and different parts of the world as well. Thus, this 
should be taken into consideration when analyzing the data from each 
of the studies.  
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Measurement of outcomes and design of the studies also varied 
and made for interesting influences on outcomes as well. Such as, 
Heiman et al12 applied the topical medication to the women in the 
clinic and visually studied the erythema, vasocongestion, lubrication, 
etc. They did state that they chose to use this subjective method 
rather than using vaginal photoplethysmography, which utilizes a 
vaginal probe, because they were more interested in studying the 
subjective assessments such as sexual arousal and sexual satisfaction. 
However, this method of utilizing subjective questionnaires and clinical 
judgment may have affected the outcomes to some extent. 
Conversely, the Liao et al study5 took a differing approach of having 
patients apply the medication to themselves, which potentiates risk 
and differences between groups. Even though allowing patients to 
apply the medication themselves, at home, and engaging in sexual 
activity with their monogamous partners, may have provided the best 
practical data for subjects since most patients whom may want to use 
this treatment are more likely to be engaging in sexual intercourse in 
their natural environments as opposed to the medical clinic.  
Lastly, psychological factors play a role in every study. Due to 
the nature of FSAD, which may be partially psychological, the 
expectation to be treated may explain why there was a significant 
improvement from baseline for the majority of measured outcomes for 
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the placebo groups in addition to the treatment groups. This especially 
holds true for the Heiman et al study12 which was a crossover study, 
thus subjects knew they would be treated at some point. In terms of 
efficacy of the medication itself, this may skew results. On the other 
hand, in terms of practical application of topical alprostadil, one must 
take into consideration if this really matters when it comes to treating 
patients. If they are getting positive results with few negative side 
effects, it may be a viable option for many individuals.  
 Further study is needed to give a more definitive answer to the 
question whether topical alprostadil is a beneficial treatment for 
women experiencing FSAD. Research potential is vast for studying and 
treating female sexual dysfunction in general. More research should be 
conducted on all the female sexual dysfunction subcategories, different 
groups of sexuality such as homosexual, bisexual, and other members 
of the LGTBQ community. Also, there should be further research on 
women on hormone replacement or utilizing differing birth control 
methods and the effect of the treatment and the differing androgens 
with and without the use of alprostadil. An ideal study would include all 
of these populations and perhaps result in getting to the root of the 
female sexual cycle and where the dysfunction is first resulting, 
making it easier to direct treatment and perhaps provide further 
understanding about female sexual dysfunction as a whole.  
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CONCLUSION 
Topical alprostadil shows great potential and is a viable option 
for the treatment of FSAD. Due to its studied efficacy and low to 
moderate adverse events reported, it is a very plausible, easy to use 
option for women who continually experience such a disabling 
disorder. There needs to be much more research on this medication as 
well as other alternatives for women who cannot tolerate the minimal 
side effects or who do not want to apply a topical cream prior to sexual 
intercourse. Either way, there needs to be much better screening in 
the medical world and awareness that these disorders do indeed exist 
and that there are a number of women who may be aware that they 
do not have to feel distressed or place their overall health, personal 
relationships, and personal well-being at risk. Overall, treating with 
alprostadil is a very suitable option for most suffers of FSAD and a 
potential treatment for other aspects of FSD as a whole.  
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Table 1: Quality Assessment of Reviewed Articles 
Outcome 
Number 
of studies 
Study 
Designs 
Downgrade Criteria 
Upgrade 
Criteria 
Quality 
Limitations Indirectness Inconsistency Imprecision 
Publication 
bias 
Sexual 
Arousal 
Rate 
2 RCT Not 
Serious 
Not Serious Not Serious  Serious a Not Serious  Dose-
Response 
Gradient 
High 
Sexual 
Satisfaction 
2 RCT Not 
Serious  
Not Serious Not Serious  Seriousa Not Serious  Dose-
Response 
Gradient 
High 
aSmall sample size 
 
Table 2. Summary of Findings Liao et al, 20085 
Efficacy Endpoint  Placebo 500 mcg 700 mcg 900 mcg 
Patient sexual arousal satisfaction 
rate, Entire treatment period-
screening period, mean (SD)  
Score 22.63 (32.70) 36.67 (38.44) 34.01 (39.21)  44.29 (39.66) 
P value  0.0224 0.0358 0.0002 
FSFI, Total, Mean (SD)  Score 14.68 (20.36) 20.71 (17.91) 21.69 (17.95) 22.89 (19.77) 
P value  0.067 0.035 0.002 
Abbreviations: Female Sexual Function Index Score Changes (FSFI), Standard Deviation (SD)  
 
